ArticleJournal of advanced pharmaceutical technology & research
Evaluation of the combination of chitosan hydrogel crosslinker and dental pulp stem cell-derived exosomes on osteoblast viability and differentiation.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: Evaluation of the combination of chitosan hydrogel crosslinker and dental pulp stem cell-derived exosomes on osteoblast viability and differentiation.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dental pulp stem cell (DPSC) has gained attention as a cell-free therapeutic approach to enhance bone regeneration. However, the degradation of exosomal biomaterials limits their application, which may be overcome by using an injectable chitosan hydrogel crosslinker (ICHC) as a natural polymeric carrier. ICHC was prepared and loaded with exosomes derived from DPSCs. Cytotoxicity, calcium deposition, nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) were conducted to assess biocompatibility, mineralization capacity, and structural characteristics. The cell viability of ICHCs, exosome 5 ng/mL, and exosome-loaded ICHC 0.6% ranged from 95% to 132%. NTA analysis revealed particle sizes of 147.5 nm for exosomes and 377.5 nm for exosome-loaded ICHC, with concentrations of 4.6 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.